The Global Human Chorionic Gonadotropin Market Size accounted for USD 812.7 Million in 2022 and is estimated to achieve a market size of USD 1,654.8 Million by 2032 growing at a CAGR of 7.5% from 2023 to 2032.

Human Chorionic Gonadotropin Market Highlights

• Global human chorionic gonadotropin market revenue is poised to garner USD 1,654.8 million by 2032 with a CAGR of 7.5% from 2023 to 2032
• North America human chorionic gonadotropin market value occupied around USD 308.3 million in 2022
• Asia-Pacific human chorionic gonadotropin market growth will record a CAGR of more than 8% from 2023 to 2032
• Among therapeutic area, the female infertility treatment sub-segment generated over US$ 341.3 million revenue in 2022
• Based on distribution channel, the hospital pharmacies sub-segment generated around 56% share in 2022
• Advancements in recombinant hCG production technology is a popular human chorionic gonadotropin market trend that fuels the industry demand

Human chorionic gonadotropin (hCG) is a hormone primarily produced by the syncytiotrophoblastic cells of the placenta during pregnancy. Its role is to sustain the pregnancy by stimulating the corpus luteum to produce progesterone. The pituitary gland, liver, and colon also produce significant amounts of hCG. These cells eventually form the placenta, which provides nourishment to the fertilized egg and attaches it to the uterine wall. hCG is a dimer composed of unique 92 amino acid alpha-subunits and 145 amino acid beta-subunits. Additionally, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH) share the same alpha-subunit.

Global Human Chorionic Gonadotropin Market Dynamics

Market Drivers

• The significant increase in infertility issues among men and women
• The rise in the prevalence of hypogonadism in the geriatric population
• Increase in awareness toward HCG among healthcare professionals and patients
• Changing lifestyle and awareness regarding the treatment of infertility

Market Restraints

• The availability of substitutes
• Cautions & warnings issued by FDA against the side effects of hCG

Market Opportunities

• Rise in popularity of fertility tourism
• The availability of advanced IVF facilities and treatment options

Human Chorionic Gonadotropin Market Report Coverage

Market	Human Chorionic Gonadotropin Market
Human Chorionic Gonadotropin Market Size 2022	USD 821.7 Million
Human Chorionic Gonadotropin Market Forecast 2032	USD 1,654.8 Million
Human Chorionic Gonadotropin Market CAGR During 2023 - 2032	7.5%
Human Chorionic Gonadotropin Market Analysis Period	2020 - 2032
Human Chorionic Gonadotropin Market Base Year	2022
Human Chorionic Gonadotropin Market Forecast Data	2023 - 2032
Segments Covered	By Technology, By Therapeutic Area, By Distribution Channel, By End-User, And By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Bristol Myers Squibb Company, Cigna, Merck & Co., Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd, Ferring Pharmaceuticals Inc, Scripps Laboratories, Lee BioSolutions Inc., Sanzyme, and LUPIN.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis

Human Chorionic Gonadotropin Market Insights

The rising prevalence of hypogonadism-related disorders in men, particularly in elderly men, is a major driver of the human chorionic gonadotropin (hCG) market. Recently, physicians have faced a unique problem when it comes to hypogonadism in men who want to keep their fertility. The population of young men with hypogonadism has risen dramatically in the last decade. These men are generally operated on with testosterone replacement therapy (TRT) that results in azoospermia and the worst-case scenario, infertility. However, human chorionic gonadotropin therapy can be helpful for hypogonadal men to reestablish or balance spermatogenesis.

With a rise in the prevalence of hypogonadism in the younger male population and the use of anabolic steroids, the importance of therapeutic human chorionic gonadotropin (hCG) treatment has grown exponentially over the last few decades. However, between 2001 and 2011, the number of men using testosterone replacement therapy (TRT) increased threefold overall, and fourfold among men aged 40–49. Furthermore, the total prevalence of hypogonadism in American men is 7% in men under the age of 40 and 38% in men over the age of 45. Anabolic androgenic steroid (AAS) use has been estimated to be as high as 3 million among American men, with a lifetime prevalence of use ranging from 3% to 4.2%. This rise has coincided with a steady rise in paternity age, posing a new challenge in treating hypogonadism and conserving fertility.

Human Chorionic Gonadotropin hGC Market Segmentation

The worldwide market for human chorionic gonadotropin is split based on technology, therapeutic area, distribution channel, end-user, and geography.

Human Chorionic Gonadotropin Technology

• Natural Source Extraction
• Recombinant Technology

Based on the technology, the natural source extraction segment is expected to have the largest human chorionic gonadotropin market share over the forecast period. The popularity of naturally extracted hCG hormone products is increasing due to the introduction of new products and widespread adoption, which will also contribute to the segment's growth during the forecast period. For nearly three decades, hCG has been extracted naturally from pregnant women's urine and used to induce midcycle follicle evolution and ovulatory in women undergoing fertility treatments. Furthermore, recombinant HCG (rHCG) has recently been developed as an alternative to naturally extracted hCG for the final maturation of oocytes in women undergoing in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Human Chorionic Gonadotropin Therapeutic Areas

• Female Infertility Treatment
• Male Hypogonadism
• Oligospermia Treatment
• Others

According to the human chorionic gonadotropin market forecast, the female infertility treatment held the largest market share in past years and is expected to continue to do so throughout the forthcoming years. This is due to an increase in infertility-related issues in females, such as polycystic ovarian syndrome (PCOS). Infertility in females can be caused by a variety of factors, including tubal disorders such as a blocked fallopian tube, polycystic ovary syndrome, uterine disorders, other follicular disorders, or an endocrine system disorder. Human chorionic gonadotropin (hCG) is a hormone that can be used to treat infertility issues and help to improve the chances of pregnancy as part of an IVF or ART cycle. With the increasing incidence of infertility in females around the globe, the demand for effective treatment is anticipated to propel the growth of the market.

Human Chorionic Gonadotropin Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the distribution channel the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. As per the hGC market analysis, hospital pharmacies dominate the market within the distribution channel segment. Hospitals and medical clinics often stock hCG products, especially for use in fertility treatments or as part of medical protocols. These are typically administered by healthcare professionals. Retail pharmacies and drugstores are common distribution channels for hCG products, particularly over-the-counter (OTC) versions or prescription-based hCG products. Customers can purchase hCG products directly from these outlets.

Human Chorionic Gonadotropin End-Users

• Fertility Clinics
• Research Institutions
• Others

Fertility clinics provide services to help with the treatment of infertility. These services include in vitro fertilization (IVF), surrogacy, artificial insemination, and other techniques that aid in the resolution of infertility problems among marriages, single mothers, as well as the LGBT community. Even so, technological developments in assisted reproductive techniques, as well as an increase in awareness about infertility treatment, are anticipated to propel the growth of the fertility clinics segment during the forecast period.

Human Chorionic Gonadotropin Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Human Chorionic Gonadotropin Market Regional Analysis

North America has been a significant contributor to the maximum revenue in recent years in the human chorionic gonadotropin (hGC) market, and this trend is expected to continue in the upcoming years. This dominance can be attributed to a significant increase in infertility-related issues in both men and women across North America. According to a study by the American Society for Reproductive Medicine, male partners are responsible for infertility in approximately 40% of infertile couples, and about 85–90% of them receive treatment through drugs or surgery. Furthermore, in the United States, approximately 300 out of every 100,000 women utilize assisted reproductive technologies (ART) annually to address infertility issues. These factors are expected to drive market growth in the North American region.

Conversely, the Asia-Pacific region is expected to witness the fastest growth in the human chorionic gonadotropin hGC market. This growth is particularly prominent in China, driven by a substantial decrease in fertility rates and an increase in the geriatric population. These factors are anticipated to be key drivers for market growth in the Asia-Pacific region.

Human Chorionic Gonadotropin Market Players

Some of the top human chorionic gonadotropin companies offered in our report includes Bristol Myers Squibb Company, Cigna, Merck & Co., Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd, Ferring Pharmaceuticals Inc, Scripps Laboratories, Lee BioSolutions Inc., Sanzyme, and LUPIN.

TABLE OF CONTENT